Shorting Volatility is Bigger, and Riskier, Than Ever

NYSE: VXX | iPath Series B S&P 500 VIX Short-Term Futures ETN News, Ratings, and Charts

VXX – Selling option premium or shorting volatility has often been compared to picking up dimes in front of a steamroller.  Despite the risks and the not-too-distant blow-up of VIX- related products earlier this year, more money than ever is piling into these strategies. Read for details.

Selling option premium or shorting volatility has often been compared to picking up dimes in front of a steamroller.  Despite the risks and the not-too-distant blow-up of VIX- related products earlier this year, more money than ever is piling into these strategies.

And recent reports and data suggest that returns are shrinking, meaning people are now picking up pennies at the risk of being flattened by an adverse event.

The short volatility trade, where investors sell options to bet against equity price swings, is becoming less profitable. The strategy has, in theory, made no money for investors — 42% of the time since 2018, according to a report from IPS Strategic Capital, compared with a recent average of about 30% since 2012.

Funds that employ a covered call or put in writing that hope to track the Chicago Board of Options Exchange (CBOE)  ‘s  Buywrite , PutWrite and Iron Condor Indexes, which are all designed to  track the S&P 500, begun to badly lag over the past few years as option premium is not rich enough to compensate for the fact the strategies have capped or limited profit potential.

The concept behind these strategies is that income received from selling the options provides a cushion against drawdowns, while clipping some potential gains.

The lagging performance is attributable to the deteriorating spread between implied and realized equity index volatility, which is known as the volatility risk premium.

The market tendency is to price in a higher cushion for price swings compared with what comes to pass giving traders an opportunity to sell options and earn a premium along the way and keep the premium as implied volatility ultimately reverts or converges with realized volatility.

In addition, to the billions of dollars in mutual funds using the buy-write or put selling, there are also billions tied to VIX-related products and their options; these ‘derivatives of derivatives’ creates highly-leveraged positions in which losses can quickly multiple during an adverse move.

All of this comes even as economic uncertainty index has moved to its highest level in 5 years.

It seems that with lowered returns and higher risk, these strategies are running on borrowed time before a spike in volatility can create a loss in a few days that wipes out years of gains.


VXX shares were trading at $20.56 per share on Tuesday afternoon, down $0.12 (-0.58%). Year-to-date, VXX has declined -56.25%, versus a 21.93% rise in the benchmark S&P 500 index during the same period.


About the Author: Option Sensei


Steve has more than 30 years of investment experience with an expertise in options trading. He’s written for TheStreet.com, Minyanville and currently for Option Sensei. Learn more about Steve’s background, along with links to his most recent articles. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
VXXGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


:  |  News, Ratings, and Charts

Investor Alert: Keep Calm and Carry On

The stock market (SPY) took a scary turn on Monday as news of Evergrande culminated in a worldwide sell off. Now with a little time and perspective investors see this was more smoke than actual fire creating a buy the dip event. Why did this happen? And where do stocks head next? Read on for those answers and more below...

:  |  News, Ratings, and Charts

2022 Stock Market Outlook

The stock market (SPY) has continued on a bullish path in 2021. Will that continue in 2022? And what could happen to awaken the bear market from hibernation? 40 year investment veteran Steve Reitmeister explores this and more in this early edition of his 2022 Stock Market Outlook. Read on for full details below...

:  |  News, Ratings, and Charts

3 Cheap Healthcare Stocks to Buy Right Now

Healthcare stocks saw renewed interest due to the onset of the pandemic, but It’s not only COVID that is driving returns. The Baby Boomer generation is getting older, which is resulting in increased demand for healthcare products and services. That’s why investors should consider adding undervalued healthcare stocks such as Ironwood Pharmaceuticals, Inc. (IRWD), Nu Skin Enterprises, Inc. (NUS), and Bristol-Myers Squibb Co. (BMY) to their portfolio.

:  |  News, Ratings, and Charts

3 Value Stocks to Buy While You Still Can

After outperforming from last fall into the spring, value stocks have been overtaken by growth stocks, but that is expected to change as the economic recovery continues. So, now is the time to start putting your money to work in undervalued companies that offer the potential for strong returns such as Gilead Sciences Inc. (GILD), HP Inc. (HPQ), and CNH Industrial N.V. (CNHI).

:  |  News, Ratings, and Charts

3 Cheap Healthcare Stocks to Buy Right Now

Healthcare stocks saw renewed interest due to the onset of the pandemic, but It’s not only COVID that is driving returns. The Baby Boomer generation is getting older, which is resulting in increased demand for healthcare products and services. That’s why investors should consider adding undervalued healthcare stocks such as Ironwood Pharmaceuticals, Inc. (IRWD), Nu Skin Enterprises, Inc. (NUS), and Bristol-Myers Squibb Co. (BMY) to their portfolio.

Read More Stories

More iPath Series B S&P 500 VIX Short-Term Futures ETN (VXX) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All VXX News